PM1022 / BioNTech - LARVOL DELTA

Phase I/II safety and preliminary efficacy of PM1022, a bispecific antibody targeting PD-L1 and TIGIT, in patients with advanced solid tumors. (ASCO 2024) - P1/2 | "PM1022 was safe and well-tolerated up to 1200 mg Q3W with preliminary anti-tumor activity. These findings could support further exploration of PM1022 in advanced solid tumors. Clinical trial information: NCT05867771."

Clinical • Metastases • P1/2 data • Esophageal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • NECTIN2 • PVR • TIGIT

A Study of PM1022 in Patients With Advanced Tumors (clinicaltrials.gov) - P1/2 | N=200 | Recruiting | Sponsor: Biotheus Inc.

Metastases • New P1/2 trial • Oncology • Solid Tumor